CN114381255A - 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 - Google Patents
一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN114381255A CN114381255A CN202111243137.6A CN202111243137A CN114381255A CN 114381255 A CN114381255 A CN 114381255A CN 202111243137 A CN202111243137 A CN 202111243137A CN 114381255 A CN114381255 A CN 114381255A
- Authority
- CN
- China
- Prior art keywords
- source
- rare earth
- radioactive
- zrf
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 61
- 150000002910 rare earth metals Chemical class 0.000 title claims abstract description 52
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 47
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 36
- 238000012879 PET imaging Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title abstract description 14
- 238000003745 diagnosis Methods 0.000 title abstract description 13
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 14
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 14
- 229910052726 zirconium Inorganic materials 0.000 claims abstract description 10
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 8
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 5
- 238000012636 positron electron tomography Methods 0.000 claims abstract 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 239000012216 imaging agent Substances 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 20
- 238000000975 co-precipitation Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 238000003384 imaging method Methods 0.000 claims description 17
- -1 trimethyl oxonium tetrafluoroborate Chemical compound 0.000 claims description 17
- 150000002500 ions Chemical class 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 229910052691 Erbium Inorganic materials 0.000 claims description 11
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- 229910052735 hafnium Inorganic materials 0.000 claims description 10
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 8
- 239000010936 titanium Substances 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 6
- 239000013110 organic ligand Substances 0.000 claims description 6
- DUFCMRCMPHIFTR-UHFFFAOYSA-N 5-(dimethylsulfamoyl)-2-methylfuran-3-carboxylic acid Chemical compound CN(C)S(=O)(=O)C1=CC(C(O)=O)=C(C)O1 DUFCMRCMPHIFTR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052765 Lutetium Inorganic materials 0.000 claims description 5
- 229910052779 Neodymium Inorganic materials 0.000 claims description 5
- 229910052775 Thulium Inorganic materials 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- MCFIMQJAFAOJPD-MTOQALJVSA-J hafnium(4+) (Z)-4-oxopent-2-en-2-olate Chemical compound [Hf+4].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O MCFIMQJAFAOJPD-MTOQALJVSA-J 0.000 claims description 4
- 229910010272 inorganic material Inorganic materials 0.000 claims description 4
- 239000011147 inorganic material Substances 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000011368 organic material Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- YOBOXHGSEJBUPB-MTOQALJVSA-N (z)-4-hydroxypent-3-en-2-one;zirconium Chemical compound [Zr].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O YOBOXHGSEJBUPB-MTOQALJVSA-N 0.000 claims description 3
- 229910052693 Europium Inorganic materials 0.000 claims description 3
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 3
- 229910052772 Samarium Inorganic materials 0.000 claims description 3
- 229910052771 Terbium Inorganic materials 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 3
- PDPJQWYGJJBYLF-UHFFFAOYSA-J hafnium tetrachloride Chemical compound Cl[Hf](Cl)(Cl)Cl PDPJQWYGJJBYLF-UHFFFAOYSA-J 0.000 claims description 3
- 229910052746 lanthanum Inorganic materials 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 claims description 3
- 229910020491 K2TiF6 Inorganic materials 0.000 claims description 2
- 229910020148 K2ZrF6 Inorganic materials 0.000 claims description 2
- 229910007828 Li2ZrF6 Inorganic materials 0.000 claims description 2
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000003980 solgel method Methods 0.000 claims description 2
- 238000005979 thermal decomposition reaction Methods 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 abstract description 51
- 238000004020 luminiscence type Methods 0.000 abstract description 23
- 230000005284 excitation Effects 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000011734 sodium Substances 0.000 description 59
- 239000000243 solution Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- 229910052769 Ytterbium Inorganic materials 0.000 description 8
- 150000001242 acetic acid derivatives Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 6
- 241000700198 Cavia Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002159 nanocrystal Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001805 chlorine compounds Chemical class 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 229910007926 ZrCl Inorganic materials 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- DBUHPIKTDUMWTR-UHFFFAOYSA-K erbium(3+);triacetate Chemical compound [Er+3].CC([O-])=O.CC([O-])=O.CC([O-])=O DBUHPIKTDUMWTR-UHFFFAOYSA-K 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- OSCVBYCJUSOYPN-UHFFFAOYSA-K ytterbium(3+);triacetate Chemical compound [Yb+3].CC([O-])=O.CC([O-])=O.CC([O-])=O OSCVBYCJUSOYPN-UHFFFAOYSA-K 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000007937 eating Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002222 fluorine compounds Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 231100000456 subacute toxicity Toxicity 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000002229 urogenital system Anatomy 0.000 description 3
- 229910003366 β-NaYF4 Inorganic materials 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 238000012984 biological imaging Methods 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- BFXAWOHHDUIALU-UHFFFAOYSA-M sodium;hydron;difluoride Chemical compound F.[F-].[Na+] BFXAWOHHDUIALU-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000001748 luminescence spectrum Methods 0.000 description 1
- NFSAPTWLWWYADB-UHFFFAOYSA-N n,n-dimethyl-1-phenylethane-1,2-diamine Chemical compound CN(C)C(CN)C1=CC=CC=C1 NFSAPTWLWWYADB-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
- C09K11/025—Use of particular materials as binders, particle coatings or suspension media therefor non-luminescent particle coatings or suspension media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7766—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing two or more rare earth metals
- C09K11/7772—Halogenides
- C09K11/7773—Halogenides with alkali or alkaline earth metal
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111243137.6A CN114381255B (zh) | 2021-10-25 | 2021-10-25 | 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 |
PCT/CN2021/129577 WO2023070743A1 (zh) | 2021-10-25 | 2021-11-09 | 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111243137.6A CN114381255B (zh) | 2021-10-25 | 2021-10-25 | 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114381255A true CN114381255A (zh) | 2022-04-22 |
CN114381255B CN114381255B (zh) | 2022-10-11 |
Family
ID=81196224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111243137.6A Active CN114381255B (zh) | 2021-10-25 | 2021-10-25 | 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114381255B (zh) |
WO (1) | WO2023070743A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116459358A (zh) * | 2023-02-27 | 2023-07-21 | 中国科学院福建物质结构研究所 | 一种稀土放射性医用核素标记的纳米材料及其制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2849162A1 (de) * | 1978-11-13 | 1980-05-14 | Kraftwerk Union Ag | Verfahren zur trennung von gasfoermigen isotopenverbindungen |
US20030094597A1 (en) * | 2001-11-16 | 2003-05-22 | Kelsey Paul V. | Isotopically enriched luminescent materials and methods of making same |
CN1715364A (zh) * | 2004-06-28 | 2006-01-04 | 通用电气公司 | 闪烁体组合物,相关工艺及制品 |
CN1798989A (zh) * | 2003-06-05 | 2006-07-05 | 科学技术基金会 | 稀土碘化物类闪烁晶体 |
CN1942783A (zh) * | 2004-04-14 | 2007-04-04 | 圣戈班晶体及检测公司 | 具有低核背景噪音的稀土基闪烁剂材料 |
CN103403126A (zh) * | 2011-04-04 | 2013-11-20 | 株式会社德山 | 闪烁体、放射线检测装置及放射线检测方法 |
CN104302731A (zh) * | 2012-03-09 | 2015-01-21 | 综合工科学校 | 稀土氧化物颗粒及其用途、特别是在成像中的用途 |
CN110105945A (zh) * | 2019-05-28 | 2019-08-09 | 上海大学 | 稳定同位素74Se标记量子点及其制备方法 |
CN110603310A (zh) * | 2018-02-07 | 2019-12-20 | 田纳西大学研究基金会 | 共掺杂有一价离子的石榴石闪烁体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100030195A (ko) * | 2008-09-09 | 2010-03-18 | 서울대학교산학협력단 | 방사성 표지된 형광 실리카 나노파티클 및 이를 이용한 pet 및 형광 복합영상 측정방법 |
CN102451476B (zh) * | 2010-10-29 | 2013-09-11 | 中国科学院化学研究所 | 具有生物相容性的放射性核素掺杂的磁性纳米晶体及其制备方法 |
CN102676172B (zh) * | 2012-04-24 | 2016-09-14 | 中国科学院福建物质结构研究所 | 稀土掺杂氟镧化钾纳米荧光标记材料及其制备方法 |
BR112017024821A2 (pt) * | 2015-05-22 | 2018-08-07 | Univ Texas | nanopartículas radioativas e métodos de fabricação e utilização das mesmas |
CN113072939B (zh) * | 2020-01-03 | 2022-07-19 | 中国科学院福建物质结构研究所 | 生物体内可降解上转换无机纳米材料及制备方法和应用 |
CN113481005A (zh) * | 2021-07-21 | 2021-10-08 | 上海应用技术大学 | 一种稀土掺杂氟化锆铯基上转换发光纳米材料及其制备方法 |
-
2021
- 2021-10-25 CN CN202111243137.6A patent/CN114381255B/zh active Active
- 2021-11-09 WO PCT/CN2021/129577 patent/WO2023070743A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2849162A1 (de) * | 1978-11-13 | 1980-05-14 | Kraftwerk Union Ag | Verfahren zur trennung von gasfoermigen isotopenverbindungen |
US20030094597A1 (en) * | 2001-11-16 | 2003-05-22 | Kelsey Paul V. | Isotopically enriched luminescent materials and methods of making same |
CN1798989A (zh) * | 2003-06-05 | 2006-07-05 | 科学技术基金会 | 稀土碘化物类闪烁晶体 |
CN1942783A (zh) * | 2004-04-14 | 2007-04-04 | 圣戈班晶体及检测公司 | 具有低核背景噪音的稀土基闪烁剂材料 |
CN1715364A (zh) * | 2004-06-28 | 2006-01-04 | 通用电气公司 | 闪烁体组合物,相关工艺及制品 |
CN103403126A (zh) * | 2011-04-04 | 2013-11-20 | 株式会社德山 | 闪烁体、放射线检测装置及放射线检测方法 |
CN104302731A (zh) * | 2012-03-09 | 2015-01-21 | 综合工科学校 | 稀土氧化物颗粒及其用途、特别是在成像中的用途 |
CN110603310A (zh) * | 2018-02-07 | 2019-12-20 | 田纳西大学研究基金会 | 共掺杂有一价离子的石榴石闪烁体 |
CN110105945A (zh) * | 2019-05-28 | 2019-08-09 | 上海大学 | 稳定同位素74Se标记量子点及其制备方法 |
Non-Patent Citations (1)
Title |
---|
FANRONG AI等: "Intrinsically 89Zr-labeled Gd2O2S:Eu nanophosphors with high in vivo stability for dual-modality imaging", 《AM J TRANSL RES》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116459358A (zh) * | 2023-02-27 | 2023-07-21 | 中国科学院福建物质结构研究所 | 一种稀土放射性医用核素标记的纳米材料及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114381255B (zh) | 2022-10-11 |
WO2023070743A1 (zh) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Recent advances in near-infrared emitting lanthanide-doped nanoconstructs: Mechanism, design and application for bioimaging | |
Dong et al. | Lanthanide nanoparticles: from design toward bioimaging and therapy | |
Yu et al. | Recent advances in rare-earth-doped nanoparticles for NIR-II imaging and cancer theranostics | |
He et al. | Enhanced up/down-conversion luminescence and heat: simultaneously achieving in one single core-shell structure for multimodal imaging guided therapy | |
Liu et al. | Controlled synthesis of uniform and monodisperse upconversion core/mesoporous silica shell nanocomposites for bimodal imaging | |
Cao et al. | Biodistribution of sub-10 nm PEG-modified radioactive/upconversion nanoparticles | |
Zhu et al. | Core–shell Fe3O4@ NaLuF4: Yb, Er/Tm nanostructure for MRI, CT and upconversion luminescence tri-modality imaging | |
CN109771442B (zh) | 一种增敏肿瘤放疗的复合纳米颗粒及其制备方法和应用 | |
US8092783B2 (en) | Gadolinium containing prussian blue nanoparticles as nontoxic MRI contrast agents having high relaxivity | |
Yi et al. | PEGylated NaLuF4: Yb/Er upconversion nanophosphors for in vivo synergistic fluorescence/X-ray bioimaging and long-lasting, real-time tracking | |
Xue et al. | Upconversion optical/magnetic resonance imaging-guided small tumor detection and in vivo tri-modal bioimaging based on high-performance luminescent nanorods | |
Li et al. | Recent advances on inorganic lanthanide-doped NIR-II fluorescence nanoprobes for bioapplication | |
Wang et al. | Upconverting rare-earth nanoparticles with a paramagnetic lanthanide complex shell for upconversion fluorescent and magnetic resonance dual-modality imaging | |
CN107551279B (zh) | 具有近红外光热效应和多模态成像功能的超小蛋白复合纳米粒及其制备方法和应用 | |
Zhang et al. | Biomedical applications of lanthanide nanomaterials, for imaging, sensing and therapy | |
WO2021134786A1 (zh) | 生物体内可降解上转换无机纳米材料及制备方法和应用 | |
Cheng et al. | Facile preparation of multifunctional WS2/WOx nanodots for chelator‐free 89Zr‐labeling and in vivo PET imaging | |
CN114381255B (zh) | 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用 | |
Godlewski et al. | New generation of oxide-based nanoparticles for the applications in early cancer detection and diagnostics | |
Wei et al. | Lanthanide‐Doped Nanoparticles with Near‐Infrared‐to‐Near‐Infrared Luminescence for Bioimaging | |
Chen et al. | Controllable fabrication of rare-earth-doped Gd2O2SO4@ SiO2 double-shell hollow spheres for efficient upconversion luminescence and magnetic resonance imaging | |
KR101507645B1 (ko) | 암 진단 및 치료용 유-무기 나노복합체 | |
Xu et al. | Recent advances in lanthanide-doped up-conversion probes for theranostics | |
CN113384697A (zh) | 针对肿瘤诊疗一体化的多功能纳米粒子及制备、应用 | |
CN103623407A (zh) | 一种集辅助肿瘤热疗与放疗功能于一体的纳米协同治疗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240524 Address after: 065000 China (Hebei) Pilot Free Trade Zone Daxing Airport Area Langfang Airport Economic Zone Hangyidao Free Trade Zone Science and Technology Innovation Base, Shijiazhuang City, Hebei Province 4671 Patentee after: Aode Rare Earth Life Technology (Hebei) Co.,Ltd. Country or region after: China Patentee after: Hong Maochun Patentee after: Liu Yongsheng Patentee after: Mindu Innovation Laboratory Address before: Fuzhou City, Fujian province 350002 Yangqiao Road No. 155 Patentee before: FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES Country or region before: China Patentee before: Mindu Innovation Laboratory |
|
TR01 | Transfer of patent right |